Baum C L, Wali R K, Sitrin M D, Bolt M J, Brasitus T A
Department of Medicine, University of Chicago Hospitals and Clinics, Pritzker School of Medicine, University of Chicago, Illinois 60637.
Cancer Res. 1990 Jul 1;50(13):3915-20.
Recently, a number of studies in experimental animals and humans have suggested that alterations in the activity of protein kinase C (PKC) may be involved in the malignant transformation process. To determine whether such alterations in this kinase were present before the development of 1,2-dimethylhydrazine (DMH)-induced colon cancers, rats were given s.c. injections of this procarcinogen (20 mg/kg body weight/week) or diluent for 10 or 15 weeks. Animals were sacrificed after these time periods and colonic epithelium was harvested from each group. The activity and distribution of PKC in the cytosolic and membrane fractions of these preparations as well as 1,2-diacylglycerol mass and phosphoinositide turnover were then examined and compared in the presence and absence of 10 nM 1,25-dihydroxycholecalciferol, an agent which has previously been found to influence these biochemical parameters in the normal rat colonic epithelium. The results of these studies demonstrate that: (a) the percentage of PKC activity in the membrane fraction was significantly greater in DMH-treated animals compared to their control counterparts at 10 and 15 weeks; (b) the total PKC activity was similar at 10 weeks, but markedly reduced in the colonic mucosa of the DMH-treated group at 15 weeks; (c) 1,2-diacylglycerol mass and phosphoinositide turnover were increased in the colonic mucosa of rats administered this carcinogen at both time points; and (d) in control, but not in DMH-treated animals, in vitro addition of 1,25-dihydroxycholecalciferol increased PKC activity, 1,2-diacylglycerol mass and phosphoinositide turnover at each of the times studied. Based on these findings, it would appear that alterations in PKC activity may play a role in the malignant transformation process of the colon in animals administered DMH.
最近,一些针对实验动物和人类的研究表明,蛋白激酶C(PKC)活性的改变可能参与了恶性转化过程。为了确定在1,2 - 二甲基肼(DMH)诱导的结肠癌发生之前该激酶是否存在此类改变,给大鼠皮下注射这种致癌物前体(20毫克/千克体重/周)或稀释剂,持续10或15周。在这些时间段后处死动物,并从每组中采集结肠上皮。然后在存在和不存在10 nM 1,25 - 二羟基胆钙化醇的情况下,检测并比较这些制剂的胞质和膜部分中PKC的活性和分布,以及1,2 - 二酰基甘油含量和磷酸肌醇周转率,此前已发现该物质会影响正常大鼠结肠上皮中的这些生化参数。这些研究结果表明:(a)与对照组相比,在10周和15周时,DMH处理的动物膜部分中PKC活性的百分比显著更高;(b)10周时总PKC活性相似,但在15周时DMH处理组的结肠黏膜中显著降低;(c)在两个时间点给予这种致癌物的大鼠结肠黏膜中,1,2 - 二酰基甘油含量和磷酸肌醇周转率均增加;(d)在对照组而非DMH处理的动物中,体外添加1,25 - 二羟基胆钙化醇在每个研究时间点均增加了PKC活性、1,2 - 二酰基甘油含量和磷酸肌醇周转率。基于这些发现,PKC活性的改变似乎可能在给予DMH的动物结肠恶性转化过程中起作用。